泰达生物(08189.HK)就SJK未支付SJKGC溢利保证差额向SJK提起仲裁
格隆汇9月4日丨泰达生物(08189.HK)公告,就收购SJKGC的51%股权事项,SJKGC于2018年度的经审核除税后溢利净额为30.5万美元,因此,差额为508.5万美元。自公司于2019年3月29日刊发年报以来,本公司一直与SJK磋商,以尝试解决有关事宜。
2019年8月1日,本公司已指示法律代理人向SJK发出函件,要求SJK于2019年8月15日或之前向本公司支付(i)差额或(ii)未支付有担保的现金股息,若未支付,本公司或会根据该协议向SJK提起仲裁程序。
2019年9月3日,本公司尚未收到SJK的任何书面回复及已向SJK发出仲裁通知书以启动仲裁程序。
公司称,根据该协议,因该协议产生或与该协议有关的任何争议均应提交仲裁及最终通过仲裁解决。因此,本公司应针对SJK提起仲裁程序而非提起诉讼。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.